Ex­clu­sive: Mt. Ever­est al­most got in the way of a tR­NA biotech, but hC Bio­science climbs to Se­ries A ex­ten­sion

A Take­da and ARCH-backed start­up look­ing to prove out the next po­ten­tial RNA gold­mine in drug R&D has se­cured more cap­i­tal en route to a 2024 clin­i­cal en­try, CEO Leslie Williams tells End­points News.

The biotech, hC Bio­science, al­most nev­er came to be. Williams was set to climb Mount Ever­est in 2020. But the Covid-19 pan­dem­ic had oth­er plans, so the vet­er­an biotech CEO had time to go full throt­tle on en­gag­ing the lab at the Uni­ver­si­ty of Iowa that pro­duced a 2019 pa­per in Na­ture Com­mu­ni­ca­tions and then se­cure the IP, gath­er feed­back from sci­en­tists and then form a sto­ry to tell in­vestors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER